Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen, a wholly owned subsidiary of Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years or older.
Histologically- or cytologically-confirmed metastatic or locally advanced unresectable platinum-resistant ovarian cancer, NSCLC, pancreatic ductal adenocarcinoma, endometrial cancer, colorectal cancer, or mesothelioma, who have relapsed or progressed following standard therapies, or for which no standard therapies are available.
An Eastern Cooperative Oncology Group performance status score of 0 or 1.
At least 1 measurable lesion at baseline based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
Archival tumor tissue or a fresh tumor biopsy during the screening period.
Adequate hepatic, renal and bone marrow function.
Participants must not have received more than 2 lines of cytotoxic systemic therapy in the metastatic setting (Parts B and C only).
You may not be if
Previously received or currently receiving any systemic anticancer therapy or focal radiotherapy within 4 weeks prior to the first dose of MesoC2 or within 2 weeks prior to the first dose of MesoC2 if the underlying disease had progressed on treatment.
Prior anti-MSLN antibody or MSLN-directed ADC (Part C only).
Unresolved toxicities from prior therapy greater than NCI CTCAE v5.0 grade 1 at the time of study treatment (except alopecia).
Inadequate hepatic dysfunction, renal function, or hematologic abnormalities.
